There are also several drugs in development (so are not FDA approved) with single agent activity in TSC tumor models; these include a MEK1/2 inhibitor (CI-1040) [70] and a dual PI3K/mTOR inhibitor (NVP-BEZ-235) [71]. The gene discussed is MTOR; the disease is tuberous sclerosis.